From its inception in 2018, Go Viral Ltd. has been focused on the development of effective and safe Oncolytic Virotherapy, initially for the treatment of Glioblastoma Multiforme (GBM), later also for other cancers, to improve patients’ survival and quality of life.
About the Go Viral Team
Key People Creating a better future for cancer therapy
Dr. Gesundheit founded Go Viral in 2018. He is researching the therapeutic effects of oncolytic viruses (OV). Dr. Gesundheit was a member of the department of Pediatric Hematology-Oncology at Soroka Hospital, Beer Sheva, the Hadassah Hospital Ein Karem in Jerusalem (Bone Marrow Transplantation unit), and at a private clinical center in Tel Aviv. Dr. Gesundheit served on the faculty of the Department of Jewish Philosophy, Hebrew University of Jerusalem and at the newly opened medical facility in Tzfat (Bar Ilan University), specializing in Medical Ethics.
He attended medical school at the University in Basel, Switzerland and did his residency in pediatrics at Hadassah Hospital in Jerusalem. Dr. Gesundheit completed a three-year fellowship in Pediatric Hematology-Oncology at the Hospital for Sick Children in Toronto, Canada. He received a Ph.D. in bioethics from the University of Toronto (2004), with a dissertation on Jewish medical ethics.
Dr. Ronald Ellis, PhD, MBA, Chief Technical Officer (CTO) at Go Viral, has over 40 years of scientific, managerial and executive R&D experience for vaccines, immunotherapeutic and biological products in start-up, small, medium and large biotech, pharma companies, and consulting. He has championed or led R&D efforts on a wide range of vaccines and immunotherapeutics from discovery or in-licensure through development and clinical phases to the stage of commercial licensure and launch in major markets, which together have annual worldwide sales >$10B. He is (co)author of >100 publications and 40 review articles, and is editor/coeditor of 8 books. He has made >100 invited presentations and chaired many sessions at international scientific conferences, has served on scientific advisory boards, and has consulted for a range of companies and universities. He is also the founding (2004) and incumbent Editor-in-Chief of the peer-reviewed indexed international journal Human Vaccines & Immunotherapeutics.
Dr. Ronny Pinkus, PhD, MBA, serves as the Head of Chemistry, Manufacturing & Controls (CMC) at Go Viral. He has over 27 years of extensive experience in the pharmaceutical and biotechnology industries. Ronny specializes in process development, scale-up, down- and up-stream processes, analytics, and CMC of biological pharmaceuticals.
His expertise encompasses good manufacturing practice (GMP) for pharmaceutical manufacturing across various product types, including AAV, Virus/Phages, recombinant proteins, small molecules, glycans, pegylation, and liposomes. Prior to joining Go Viral, Ronny held several scientific and managerial positions at InterPharm, Merck Serono, Teva Pharmaceuticals Industries, InSight Biopharmaceuticals, BiomX, Moebius Medical, and Bioimmunate.
Ronny obtained his PhD from the Weizmann Institute and his MBA from the Polytechnic Institute of New York.
Dr. Charles Piwko, PharmD, PhD, MSc, responsible for business development at Go Viral, has over 25 years of experience in the pharmaceutical, biotechnology, and medical device industries conducting mainly health outcomes and economic research, identifying the benefits and value of innovative therapies. Dr Piwko is a strategic thinker and contingency planner. He has analytical skills for integrating and interpreting interdisciplinary projects. Dr. Piwko has assisted pharmaceutical start-up companies to develop and implement business plans and strategies.
He holds a Pharmacy Doctor degree and a PhD in Pharmacology both from the Swiss Federal Institute of Technology in Zürich (ETH), Switzerland and an MSc in Health Administration (Health Economics) from the University of Toronto, Canada.